|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Organizational Identifiers** |  |  |
|  | VAMC  CONTROL  QIC  BEGDTE  REVDTE | Facility ID  Control Number  Abstractor ID  Abstraction Begin Date  Abstraction End Date | Auto-fill  Auto-fill  Auto-fill  Auto-fill  Auto-fill |  |
|  |  | **Patient Identifiers** |  |  |
|  | SSN  PTNAMEF  PTNAMEL  BIRTHDT  SEX  MARISTAT  RACE | Patient SSN  First Name  Last Name  Birth Date  Sex  Marital Status  Race | Auto-fill: no change  Auto-fill: no change  Auto-fill: no change  Auto-fill: no change  Auto-fill: **can change**  Auto-fill: no change  Auto-fill: no change |  |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1 | psatest | During the past year, is there documentation in the record of a Prostate Specific Antigen (PSA) based screening test?   1. Yes 2. No | 1,2  If 2, go to prevpsa | Please review all lab reports and notes for documentation of a PSA-based screening test completed during the past year.  **PSA-based screening tests include:**   * Prostate specific antigen (PSA) test * PSA Free (mass/volume) in serum or plasma * PSA Free/PSA total in serum or plasma * PSA (mass/volume) in serum or plasma * PSA protein bound (mass/volume) in serum or plasma * PSA (mass/volume) in serum or plasma by detection limit (<=0.01 ng/ml) * PSA (mass/volume) in serum or plasma by immunoassay * PSA Free (mass/volume) in serum or plasma by immunoassay   **Suggested data source**: lab reports |
| 2 | psatestdt | Enter the date of the most recent PSA-based screening test. | mm/dd/yyyy   |  | | --- | | <= 1 year prior to or = stdybeg and <= stdyend | | Enter the date of the most recent PSA-based screening test. |
| 3 | prevpsa | During the timeframe from (computer display stdybeg – 2 years to stdybeg – 1 year), is there documentation of a PSA-based screening test result?   1. Yes 2. No | 1,2  If 2, go to psacandx | Please review all lab reports and notes for documentation of a PSA-based screening test completed during the year previous to the study year.  **PSA-based screening tests include:**   * Prostate specific antigen (PSA) test * PSA Free (mass/volume) in serum or plasma * PSA Free/PSA total in serum or plasma * PSA (mass/volume) in serum or plasma * PSA protein bound (mass/volume) in serum or plasma * PSA (mass/volume) in serum or plasma by detection limit (<=0.01 ng/ml) * PSA (mass/volume) in serum or plasma by immunoassay * PSA Free (mass/volume) in serum or plasma by immunoassay   **Suggested data source**: lab reports |
| 4 | psatestdt2 | Enter the date of the most recent PSA-based screening test completed during the year prior to the study year. | mm/dd/yyyy   |  | | --- | | <= 2 years prior to stdybeg and >1 year prior to stdybeg | | Enter the date of the most recent PSA-based screening test completed during the year prior to the study year. |
| 5 | psaelev | Did any PSA-based screening test completed during timeframe from (computer display stdybeg – 2 years to stdybeg – 1 year), indicate an elevated result?   1. Yes 2. No | 1,2  If 2, go to psacandx | Please review the PSA test result and compare to the lab reference range on the report.  Typically a PSA result > 4.0 nanograms/milliliter (ng/mL) is considered elevated. |
| 6 | psaelevdt | Enter the date of the most recent elevated PSA test result reported during the timeframe from (computer display stdybeg – 2 years to stdybeg – 1 year). | mm/dd/yyyy   |  | | --- | | <= 2 years prior to stdybeg and >1 year prior to stdybeg | | Enter the date of the most recent PSA-based screening test with an elevated result. |
| 7 | psacandx | Prior to (computer display psatestdt), is there physician/APN/PA documentation of prostate cancer diagnosis?   1. Yes 2. No | 1,2 | The diagnosis of prostate cancer must be documented in the medical record by a physician/APN/PA.  Prostate cancer diagnosis documented on a Problem List must be validated by physician/APN/PA documentation in the medical record.  **Prostate cancer diagnosis includes:**   * C61 Malignant neoplasm of prostate * D075 Carcinoma in situ of prostate * D400 Neoplasm of uncertain behavior of the prostate * Z1503 Genetic susceptibility to malignant neoplasm of prostate * Z8546 Personal history of malignant neoplasm of prostate   **Suggested data sources**: Progress notes, consultations, pathology reports, operative reports |
| 8 | psadys | During the timeframe (computer to display computer display stdybeg – 2 years to stdyend), is there physician/APN/PA documentation of dysplasia of the prostate?   1. Yes 2. No | 1,2 | **Dysplasia of the prostate includes:**  Dysplasia of prostate, unspecified dysplasia of prostate, prostatic intraepithelial neoplasia, atypical small acinar proliferation of prostate, other dysplasia of prostate  **Dysplasia of the prostate must be documented in the medical record by a physician/APN/PA.**  **Suggested data sources**: Progress notes, consultations, pathology reports, operative reports |
| 9 | alpreinh | During the timeframe from (computer display stdybeg – 1 year to stdyend), was the patient prescribed a 5-alpha reductase inhibitor (finasteride or dutasteride)?   1. Yes 2. No | 1,2 | **5-alpha reductase inhibitors include finasteride (Proscar, Propecia) and dutasteride (Avodart).**  If finasteride or dutasteride was prescribed for the patient anytime during the past year, select value 1.  **Suggested data sources:** clinic notes, physician orders, medication refills |
| 10 | hospice | During the timeframe from (computer display stdybeg – 1 year to stdyend), is there documentation the patient was enrolled in hospice?   1. Yes 2. No | 1,2 | **Documentation must clearly indicate the patient was enrolled/admitted to hospice anytime during the specified timeframe.**  The hospice program may be VHA or Community-based.  **Exclude:** Comfort care, DNR, DNI, palliative care  **Suggested data sources**: consultations, progress notes |